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Alzheimer’s Disease (AD) features the accumulation of β-amyloid and Tau aggregates,
which deposit as extracellular plaques and intracellular neurofibrillary tangles (NFTs),
respectively. Neuronal Tau aggregates may appear early in life, in the absence of clinical
symptoms. This occurs in the brainstem reticular formation and mostly within Locus
Coeruleus (LC), which is consistently affected during AD. LC is the main source of
forebrain norepinephrine (NE) and it modulates a variety of functions including sleep-
waking cycle, alertness, synaptic plasticity, and memory. The iso-dendritic nature of LC
neurons allows their axons to spread NE throughout the whole forebrain. Likewise, a
prion-like hypothesis suggests that Tau aggregates may travel along LC axons to reach
out cortical neurons. Despite this timing is compatible with cross-sectional studies,
there is no actual evidence for a causal relationship between these events. In the
present mini-review, we dedicate special emphasis to those various mechanisms that
may link degeneration of LC neurons to the onset of AD pathology. This includes the
hypothesis that a damage to LC neurons contributes to the onset of dementia due to a
loss of neuroprotective effects or, even the chance that, LC degenerates independently
from cortical pathology. At the same time, since LC neurons are lost in a variety of
neuropsychiatric disorders we considered which molecular mechanism may render
these brainstem neurons so vulnerable.
Keywords: neurofibrillary tangles, basal forebrain nuclei, phospho-Tau, amyloid, mild cognitive impairment,
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INTRODUCTION
Alzheimer’s Disease (AD) affects more than 45 million of people worldwide (Alzheimer’s Disease
International, 2015). Despite research efforts, key molecular mechanisms of disease remain
uncertain. Milestones in AD pathology consist in alterations of the cytoskeleton-associated Tau
protein along with abnormal β-amyloid (Aβ) depositions. A long-lasting time interval exists
since the onset of early pathological alterations until the appearance of cognitive deterioration.
In fact, a sub-clinical phase, in which cortical AD pathology occurs in the absence of a frank
cognitive impairment is documented. Such a stage, in which a cognitive intact subject already
bears AD markers is defined ‘‘pre-clinical asymptomatic at-risk for AD’’ (Dubois et al., 2014).
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We wish to emphasize that, despite being a fascinating
hypothesis, the causal relationship between Tau pre-clinical
pathology and later cognitive deterioration remains to be
established. Cortical pathology consists of: (i) argyrophilic
structures formed by abnormal intracellular aggregates of
phospho-Tau (P-Tau) fibrils, known as neurofibrillary tangles
(NFT); and (ii) extracellular aggregates of Aβ known as amyloid
plaques (Hyman et al., 2012; Montine et al., 2012).
An updated hypothesis considers six stages of NFT pathology.
At stage I, a low amount of Gallyas-positive NFT is present,
mainly within the trans-entorhinal region, which corresponds
to the peripheral entorhinal cortex (Braak and Braak, 1991 or
the parahippocampal gyrus facing the fusiform gyrus with the
collateral sulcus interposed (Taylor and Probst, 2008). At stage I
scattered NFT can be detected also within entorhinal mesocortex,
CA1, dorsomedial thalamus and basal forebrain nuclei (Braak
and Braak, 1991). At stage II the trans-entorhinal cortex is more
affected, while the entorhinal mesocortex is consistently affected
along with CA1 and prosubiculum; dorsomedial thalamus and
basal forebrain nuclei appear as at stage I. At stage III, NFT
densely cluster in the superficial layer of both trans-entorhinal
and entorhinal cortex, while hippocampal involvement extends
towards subiculum. Isocortex (neocortex) is spared apart from
a few NFT within associative ventral areas. At stage IV all
layers of trans-entorhinal and entorhinal cortex are filled with
NFT, while the CA1 region features ghost tangles, and the basal
frontal and insular isocortex are involved. At this stage also
the amygdala and endopiriform nucleus feature NFT. At stage
V, the parasubiculum and the whole hippocampal formation
are involved massively in a continuum with trans-entorhinal
and entorhinal cortex. Remarkably, CA2 is mostly spared along
with dentate gyrus (Dudek et al., 2016). This is reminiscent of
hippocampal damage following seizures and ischemia (Giorgi
et al., 2008). At this stage the associative isocortex is widely
affected. Finally, at stage VI, primary sensory and motor
areas are affected. In most patients stage I and II are rather
asymptomatic, while during stage III memory impairment may
appear.
Aβ aggregates follow an opposite spreading direction (Thal
et al., 2002) since they first appear in the isocortex (phase 1)
and later on within allocortex (phase 2), then downstream to
diencephalon (phase 3) and furtherly towards brainstem nuclei
including substantia nigra (phase 4). In the last step Aβ extends
to caudal reticular nuclei including locus coeruleus (LC; phase 5).
The spreading of NFT through interconnected brain regions
may occur trans-synaptically via a prion-like transmission of
Tau (Mohamed et al., 2013; Goedert, 2015). These synaptic
mechanisms of degeneration are supposed to start caudally
within the iso-dendritic core of the reticular formation. In
fact, LC and other reticular nuclei feature an impressive
collateralization allowing a single axon to innervate multiple
brain regions making these cells ideal spreading vectors. A
variety of brainstem reticular nuclei features NFT. Similarly,
when considering cortical neurons long-projecting pyramidal
cells of layer V or hippocampal pyramidal cells appears more
vulnerable to degeneration (Ovsepian et al., 2016; Schaeffer
et al., 2017). The present review emphasizes the role of LC as a
powerful brainstem nucleus, which projects mono-synaptically
to all cortical regions (Nagai et al., 1981). Nonetheless, while
writing this article we already feel the limits of such a LC-centered
hypothesis, since other nuclei such as the rostral dorsal raphe,
the parabrachial nuclei and the pedunculopontine nucleus are
important as well. Thus, the LC should be regarded more
as a paradigm, rather than the unique anatomical entity,
which connects NFT pathology from the brainstem to the
cortex.
The trans-synaptic spreading of Tau from LC to other brain
regions may occur ‘‘a rebour’’ (i.e., in opposite directions) by
hippocampal injections of Tau fibrils, which produce a frank
pathology down to the LC (Iba et al., 2015).
TAU PATHOLOGY OCCURS EARLY WITHIN
BRAINSTEM, CORTICAL-PROJECTING
NUCLEI
Recent studies indicate early impairment of LC with potential
outcomes on preclinical staging and neurobiology of disease
(Braak et al., 2011). In detail, stereology consistently evidenced
that the number of LC neurons negatively correlates with
AD pathology. Pioneer studies by Tomlinson et al. (1981),
Bondareff et al. (1982) and Mann et al. (1982, 1984) described
a reduction of LC neurons in AD patients. A few years later
Chan-Palay and Asan (1989) proposed a rostro-caudal gradient
of neuronal loss within LC of AD patients, differently from PD
patients where LC is uniformly affected. In a large series of
non-selected brains (N > 2300), Braak et al. (2011) by using
P-Tau antibodies detected ‘‘pre-tangle material’’ (negative for
Gallyas reaction) within LC of almost all the brains in the
absence of Tau-related pathology in the trans-entorhinal region.
This emphasizes the occurrence of subcortical deposition of
Tau in the absence of NFT in any cortical area (less than
stage I). Depending on the severity of brainstem involvement, a
progressive staging (‘‘a’’, ‘‘b’’, ‘‘c’’) up to early cortical recruitment
(stages ‘‘1a’’ and ‘‘1b’’) is described (Table 1). These stages
are age-related, being stages ‘‘a-c’’ present solely at age 20–30,
while stages > I–II being detected only after the age of 40.
These findings lead to the following statements: (i) LC features
abnormal Tau deposits before a frank neuronal loss; (ii) Tau
deposits in LC occur decades before the average onset of cortical
AD pathology; (iii) P-Tau accumulation is likely to be key
in the process of NFT formation; and (iv) Tau alterations
anticipate dementia. The latter observation challenges quite
directly the classic amyloid cascade hypothesis, according to
which, an impairment in Aβ-pathway may trigger Tau pathology
(Hardy and Selkoe, 2002; Jack et al., 2010). In contrast, one
might hypothesize that early Tau pathology predisposes to Aβ
accumulation, which in turn exacerbates Tau pathology. Very
recently, Theofilas et al. (2017) applied up-to-date stereology to
brains at various disease stages and showed a two-fold increase
in P-Tau positive LC neurons from pre-stage 1 to stage I, with
a positive correlation between the number of P-Tau positive
cells in the LC and disease stage. They also found that volume
in the rostral part of LC decreases already from pre-stage 1 to
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TABLE 1 | Staging of neurofibrillary tangles (NFT-related) pathology in Locus coeruleus (LC).
Subcortical pretangles stages a P-Tau accumulation within the axon hillock of brainstem reticular neurons, mostly
LC neurons.
b P-Tau accumulation extended further into LC cell bodies.
Pretangle Stages c Involvement of other reticular (or reticular-related) ascending nuclei (e.g., dorsal
raphe nucleus, nuclei of the basal forebrain).
Cortical pretangles stages 1a Pre-tangle material in LC axons within the trans-entorhinal and entorhinal regions.
1b Pre-tangle inclusions within pyramidal cells of the trans-entorhinal region
connected with NFT positive axons.
stage I. The number of LC neurons decreases form stage II
onward. In another study in asymptomatic patients, Andrés-
Benito et al. (2017) confirmed these data. On the other hand,
these studies are grounded on static descriptions, where a
dynamic mechanism remains at hypothetical level. The cross-
sectional evidence reported in these studies does not represent
a proof of principle for an actual spreading of pathology. Thus,
casualty cannot be ruled out and a supreme vulnerability of
LC neurons represents a sort of background noise occurring
in a number of neurological disorders encompassing AD, PD,
seizures, multiple system atrophy, Down syndrome and many
others (Fornai, 2007; Phillips et al., 2016). In fact, the loss of
brain norepinephrine (NE) levels characterizes a number of
neurological patients and involves multiple brain areas (Gesi
et al., 2000; Giorgi et al., 2003, 2004; Marien et al., 2004;
Fornai et al., 2011; Ruffoli et al., 2011; Pifl et al., 2012,
2013) and various experimental neurological disorders (Fornai
et al., 1995a,b, 1997a,b, 1998, 1999, 2007; Siciliano et al.,
1999; Soldani and Fornai, 1999; Ferrucci et al., 2002, 2013;
Fulceri et al., 2004; Giorgi et al., 2006; Weinshenker et al.,
2008).
THE NEUROANATOMY OF LC IN AD
LC is a tube-like shaped group of NE neurons placed in
the upper part of the pons; it is composed of medium-
sized neurons (Brodal, 1981). LC extends rostrocaudally for
approximately 16 mm (German et al., 1988; Baker et al.,
1989; Halliday, 2004). These neurons send their branched
axons to innervate the entire cerebral cortex (Nagai et al.,
1981). Thus, by releasing NE through ‘‘bouton en passage’’
(or synaptic varicosities), LC modulates the activity of several
cortical areas. In fact, LC modulates sleep/wake cycle, learning
and memory, early gene expression and neuroprotection (Fornai
et al., 1990; Foote et al., 1991; Cirelli et al., 1996; Cirelli
and Tononi, 2000; Giorgi et al., 2003, 2004; Aston-Jones,
2005; Aston-Jones et al., 2007; Fornai, 2007; Giorgi et al.,
2008; Weinshenker et al., 2008; Sara, 2009; Fornai et al.,
2011; Counts and Mufson, 2012; Ferrucci et al., 2013). LC
mostly innervates limbic cortex compared with neocortex (here
defined as isocortex, Jones and Yang, 1985; Loughlin et al.,
1986; Giorgi et al., 2003). The ventral part of caudal LC
sends projections even to lower medulla and spinal cord, and
regulates autonomic functions (Ward and Gunn, 1976), while
neurons which innervate the allocortex are placed in the rostral
part of the nucleus (Ward and Gunn, 1976; Loughlin et al.,
1986).
The projection of LC neurons to the cortex may occur
monosynaptically (Fallon et al., 1978; Nagai et al., 1981; Harley,
1987), via the allothalamus (Krout et al., 2002; Garcia-Rill et al.,
2013), or through basal cholinergic nuclei. These are severely
involved in AD (Davies and Maloney, 1976; Coyle et al., 1983;
Sassin et al., 2000). In particular, degeneration of Ch1 and
Ch2 neurons is responsible for the loss of septo-hippocampal
connections leading to memory impairment (Gertz et al., 1987;
Brayda-Bruno et al., 2013). The Ch4 (nucleus basalis of Meynert)
nuclear complex, which is divided into various subfields
(Mesulam, 2013) and receives dense NE projections from LC
degenerates as well (Mesulam et al., 1983a,b, 1984; Mesulam
and Geula, 1988; Smiley and Mesulam, 1999; Haghdoost-Yazdi
et al., 2009). The Ch4 sends a strong cholinergic input to
allocortical and mesocortical areas (Mesulam et al., 1986).
In line with this, the joint involvement of cholinergic and
NE nuclei encoding motivational salience in spatial attention
explains the loss of motivational information and spatial
attention that is critically lost in dementia (Mohanty et al.,
2008; Sara, 2015; Chandler, 2016). Another limbic region
innervated by LC is the amygdala (Asan, 1998) which is
involved in AD (Knafo, 2012). The entorhinal and trans-
entorhinal cortex as well as the hippocampal formation are
monosynaptically innervated by LC (Fallon et al., 1978; Room
and Groenewegen, 1986; Harley, 1987). Entorhinal cortex
is involved in memory consolidation and retrieval (Dolcos
et al., 2005; Bott et al., 2016; Cho et al., 2016; Fayed et al.,
2017). Within hippocampus, LC axons innervate the stratum
radiatum of CA1 and stratum lucidum of CA3 (Melander
et al., 1986; Moudy et al., 1993). Despite a preferential limbic
innervation which is in line with AD pathology, a fine anatomical
analysis of the cytotectonic pattern of LC innervation within
allocortex does not provide any site-specificity which may
justify a preferential damage to layer V long-projecting neurons
which occurs in AD. In fact, the pattern of catecholamine
innervation is rather uniform in the various layers of the
allocortex (apart from the scarce density in layer I; Gaspar
et al., 1989). This rules out a site-specific, disease-related synaptic
contact with those cortical cells (pyramidal) which are mostly
affected in AD. Thus, there is no anatomical overlapping
between the fine pattern of NE innervation and the fine
pattern of neuropathology within various cortical layers. Such
a discrepancy also applies to NE innervation of isocortical
(neocortical regions; Gaspar et al., 1989). Remarkably, albeit
primary sensorimotor regions are affected only at latest AD
stages, they possess the highest NE innervation among isocortical
regions (Gaspar et al., 1989). Thus, we have to rule out a
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point-by-point matching between NE axons and degenerating
cortical neurons, which in turn rules out a trans-synaptic
disease spreading between NE fibers and cortical neurons.
This calls for considering alternative mechanisms, which may
link a damage to LC axons to cortical degeneration. In fact,
when analyzing the pattern of NE release rather than a point-
by-point connection between pre- and post-synaptic sites a
massive extra-synaptic neurotransmitter diffusion takes place.
In fact, NE release allows the amine to affect close glial cells
and brain vessels (Stone and Ariano, 1989; Toussay et al.,
2013).
THE MECHANISMS WHICH MAY LINK LC
DEGENERATION TO AD
In early studies LC neurons were quantified without stereology.
This explains a great variability in LC cell counts even within
control subjects.
Modern stereology confirms LC neuronal loss (Grudzien
et al., 2007; Counts and Mufson, 2010; Kelly et al., 2017). P-Tau
positive LC neurons are associated with a dramatic reduction of
synaptophysin-positive perineural dots, which leads to a loss of
synaptic connectivity, a sort of anatomical de-afferentiation of
these neurons from activating inputs (Andrés-Benito et al., 2017).
These authors found over-expression of α2-adrenergic receptors
at stage I, while these receptors were reduced at stage IV in the
hippocampus (Andrés-Benito et al., 2017).
Altogether these pieces of information suggest that P-Tau
accumulates within LC very early, producing subtle, yet
potentially relevant, functional alterations affecting NE release in
target areas.
P-Tau pre-tangles accumulate within pyramidal cortical
limbic cells after NE axon terminals are filled with pre-tangles
themselves (pre-tangle stage 1b). Later on, the occurrence of
NFT inclusions in trans-enthorinal cortical neurons parallels
the increase of P-Tau inclusions within LC axons, and spreads
to other cortical structures (Braak et al., 2011). At stage III,
when prodromal form of AD may appear, P-Tau burdens in
LC neurons are severe enough to cause neuronal death. Early
pre-tangle impairment of LC leads to an altered pattern of NE
release within target regions. In baseline conditions NE release
is finely tuned, and it is regulated by strong afferents from
different sensory inputs (Samuels and Szabadi, 2008) which
are altered early in the course of disease (Andrés-Benito et al.,
2017), making surviving LC cells less effective. The specific
anatomy of LC neurons makes them ideal vectors throughout
the CNS. In fact, Tau aggregates may pass trans-synaptically
from LC axons to cortical neurons and from one cortical region
to another and back again (Mohamed et al., 2013; Goedert,
2015).
At advanced stages, the loss of NE neurons enhances
the accumulation of Aβ in cortical regions: this in line
with experimental evidence. In fact, the neurotoxin DSP-4
(which causes selective degeneration of LC axons, Fornai
et al., 1996) enhances Aβ plaque accumulation in the brain
(Heneka et al., 2006). Thus, the loss of NE appears to directly
foster Aβ plaque accumulation (Kalinin et al., 2007) and LC
FIGURE 1 | Molecular events occurring in Alzheimer’s Disease (AD) following
locus coeruleus (LC) norepinephrine (NE) loss and autophagy impairment. At
LC pre-synaptic terminal. Decreased expression of β2-adrenergic receptors in
the pre-synaptic terminal leads to autophagy suppression. Oxidative stress,
NE decrease and IP3 all contribute to endoplasmic reticulum stress and
impairment of proteins processing, folding and trafficking in the trans-Golgi
network. Aβ oligomers seeds, deriving from an amyloidogenic cleavage of
APP, as well as Tau protein, are engulfed into vesicles and released into the
axo-somatic synaptic cleft. At post-synaptic cortical neuron. (1) Aβ and Tau
seeds are spread into the synaptic cleft and internalized into the cell body of
the cortical neuron. (2) The loss of β2-adrenergic receptors (β2R) stimulation
decreases autophagy. Thus the lack of NE, cannot exert its protective effect in
the cell, it drives a cascade of detrimental intracellular effects instead.
(3,4) Ca2+ entry into the cell, increase of cAMP levels, activation of PKA and
PI3K/AKT/mTOR pathway lead to a further inhibition of autophagy. (A–G) PKA
hyper-phosphorylates Tau protein (A) which leads to microtubules disgregation
(B) and to the formation of neurofibrillary tangles (NFTs). (C) These effects
translate into mitochondrial damage (D), Golgi fragmentation due to the
inactivation of associated binding proteins (E) and ER stress (F). These events
disrupt the Unfolded Protein Response (UPR) which does not provide for a
proper intracellular trafficking, processing and sorting of misfolded Aβ, leading
to further increase of harmful oligomers into the cell (G). Misfolded proteins are
internalized into the endosomal compartment but autophagy impairment does
not allow their removal and fosters trans-synaptic propagations.
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degeneration alters microglial activity, which may indirectly
induce amyloid mismetabolism (Heneka et al., 2010). These
changes correlate with cognitive impairment (Jardanhazi-Kurutz
et al., 2011).
Again, a damage to LC produces a lack of neuroprotection.
In fact β2-receptor stimulation is key in activating autophagy
(Aránguiz-Urroz et al., 2011; Farah et al., 2014; Wauson
et al., 2014) which removes P-Tau from the trans-Golgi
network.
A recent study demonstrates an accumulation of P-Tau
pyramidal cell bodies from AD patients correlates with
alterations of the Golgi apparatus (Antón-Fernández et al., 2017).
A lack of β2-mediated autophagy stimulation both on
pre-synaptic LC axons and post-synaptic cortical neurons might
be key in triggering NFT (Figure 1). Similarly, the loss of
β-receptors stimulation leads to a decrease in growth factors
expression (Follesa and Mocchetti, 1993) and permanently alters
immediate-early-genes expression (Cirelli and Tononi, 2000).
Most directly, NE activation of neurotrophic pathways was
shown to protect against neuronal amyloid toxicity (Counts and
Mufson, 2010). Again, NE innervations, which occur following a
volume transmission, may alter a variety of anatomical structures
including astrocytes, glial cells and blood vessels which can be
reached through a paracrine diffusion of NE (Stone and Ariano,
1989; Stone and John, 1991; Gesi et al., 2000; Marien et al., 2004).
In this way, the neurovascular unit can be affected at multiple
levels by a lack of NE innervation (Lecrux and Hamel, 2016).
For instance, LC activation increases brain perfusion which
triggers over-activity of multiple cortical cells (Toussay et al.,
2013). This may contribute to explain why in vascular dementia
Tau and amyloid accumulation occur as well (Mendel et al.,
2010; Day et al., 2015; Saito et al., 2015). On the other hand,
one should consider the chance that co-transmitters released
in concomitancy with NE may participate to neuroprotective
effects. This is the case of adenosine, which is known to
be neuroprotective, as well as galanine, and others (Crawley,
1993, 1996; Stone et al., 2009; Huang et al., 2011). Just
like NE these co-transmitters act by increasing autophagy,
which removes both Tau and Aβ, while inducing a higher
perfusion rate in the neurovascular unit and by modulating Ach
release.
The time window, lasting years, from the onset of P-Tau
accumulation in the LC to the onset of LC neuronal loss,
might be the best timing for trying to halt AD onset and
progression (Mather and Harley, 2016; Ehrenberg et al., 2017).
Thus, molecular mechanisms and sub-cellular sites, which first
accumulate P-Tau under the effects of NE loss, need to be
investigated. The high vulnerability of the isodendritic cells of
the LC reticular neurons relies on the archaic nature of these
cells which are preserved to transmit multimodal activities and
do not develop effective protective mechanisms (Theofilas et al.,
2015; Gambardella et al., 2017). In fact, these neurons are
sensitive to a wide spectrum of stressful stimuli. This implies
the convergency of a number of excitatory pathways making
these cells a paradigm for critical overstimulation within the
brain. A balanced stimulation of the autophagymachinery, which
removes both Tau and Aβ could be an important step in relenting
the neurobiology of disease.
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